Literature DB >> 7722300

V7, a novel leukocyte surface protein that participates in T cell activation. II. Molecular cloning and characterization of the V7 gene.

C L Ruegg1, A Rivas, N D Madani, J Zeitung, R Laus, E G Engleman.   

Abstract

V7 is a cell surface glycoprotein expressed on Ag-activated T cells, monocytes, and granulocytes, as well as subpopulations of T cells and accessory cells present in thymic medulla and tonsil. A mAb directed against V7 inhibits the proliferative response of T cells to allogeneic cells or immobilized anti-CD3 Ab, but not lectin mitogens, suggesting that V7 plays a role in TCR/CD3-mediated T cell activation. We have used the anti-V7 Ab in eukaryotic expression cloning experiments to isolate a cDNA clone containing a 3,340-bp insert that encodes V7 when transiently expressed in simian and murine fibroblastoid cells. DNA sequence analysis revealed a novel 1,021-amino acid open reading frame the structure of which conforms to the category of type I integral membrane proteins. The protein sequence includes a 20-residue putative hydrophobic signal sequence followed by a putative extracellular domain of 934 amino acids, a prototypic hydrophobic transmembrane spanning a domain of 25 residues, and finally a short and highly charged putative cytoplasmic domain of 42 residues. The extracellular domain contains seven pairs of regularly spaced cysteine residues, suggestive of Ig-like domains. On the basis of statistical analysis of the sequences of the putative cysteine loops, all seven of the Ig-like domains belong to the variable, or V-type, category. By using fluorescence in situ hybridization, we have mapped the V7 gene to human chromosome Ip13. Thus, the V7 glycoprotein represents a novel member of the Ig superfamily that is involved in critical intracellular signals essential for immune function.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7722300

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Identification of Cd101 as a susceptibility gene for Novosphingobium aromaticivorans-induced liver autoimmunity.

Authors:  Javid P Mohammed; Michael E Fusakio; Daniel B Rainbow; Carolyn Moule; Heather I Fraser; Jan Clark; John A Todd; Laurence B Peterson; Paul B Savage; Marsha Wills-Karp; William M Ridgway; Linda S Wicker; Jochen Mattner
Journal:  J Immunol       Date:  2011-05-25       Impact factor: 5.422

2.  Low-copy repeats mediate the common 3-Mb deletion in patients with velo-cardio-facial syndrome.

Authors:  L Edelmann; R K Pandita; B E Morrow
Journal:  Am J Hum Genet       Date:  1999-04       Impact factor: 11.025

3.  Nucleotide substitutions in CD101, the human homolog of a diabetes susceptibility gene in non-obese diabetic mouse, in patients with type 1 diabetes.

Authors:  Misako Okuno; Yoshihito Kasahara; Masafumi Onodera; Noriyuki Takubo; Michiko Okajima; Shigeru Suga; Nobuyuki Watanabe; Junichi Suzuki; Tadayuki Ayabe; Tatsuhiko Urakami; Tomoyuki Kawamura; Nobuyuki Kikuchi; Ichiro Yokota; Toru Kikuchi; Shin Amemiya; Kazuhiko Nakabayashi; Keiko Hayashi; Kenichiro Hata; Yoichi Matsubara; Tsutomu Ogata; Maki Fukami; Shigetaka Sugihara
Journal:  J Diabetes Investig       Date:  2016-11-25       Impact factor: 4.232

4.  Genetic and functional data identifying Cd101 as a type 1 diabetes (T1D) susceptibility gene in nonobese diabetic (NOD) mice.

Authors:  Jochen Mattner; Javid P Mohammed; Michael E Fusakio; Claudia Giessler; Carl-Philipp Hackstein; Robert Opoka; Marius Wrage; Regina Schey; Jan Clark; Heather I Fraser; Daniel B Rainbow; Linda S Wicker
Journal:  PLoS Genet       Date:  2019-06-14       Impact factor: 5.917

5.  The role of CD101-expressing CD4 T cells in HIV/SIV pathogenesis and persistence.

Authors:  Zachary Strongin; Timothy N Hoang; Gregory K Tharp; Andrew R Rahmberg; Justin L Harper; Kevin Nguyen; Lavinia Franchitti; Barbara Cervasi; Max Lee; Zhan Zhang; Eli A Boritz; Guido Silvestri; Vincent C Marconi; Steven E Bosinger; Jason M Brenchley; Deanna A Kulpa; Mirko Paiardini
Journal:  PLoS Pathog       Date:  2022-07-22       Impact factor: 7.464

6.  CD101 genetic variants modify regulatory and conventional T cell phenotypes and functions.

Authors:  Laura E Richert-Spuhler; Corinne M Mar; Paurvi Shinde; Feinan Wu; Ting Hong; Evan Greene; Sharon Hou; Katherine Thomas; Raphael Gottardo; Nelly Mugo; Guy de Bruyn; Connie Celum; Jared M Baeten; Jairam R Lingappa; Jennifer M Lund
Journal:  Cell Rep Med       Date:  2021-06-15

7.  CD101 inhibits the expansion of colitogenic T cells.

Authors:  R Schey; H Dornhoff; J L C Baier; M Purtak; R Opoka; A K Koller; R Atreya; T T Rau; C Daniel; K Amann; C Bogdan; J Mattner
Journal:  Mucosal Immunol       Date:  2016-01-27       Impact factor: 7.313

8.  Whole genome sequencing of extreme phenotypes identifies variants in CD101 and UBE2V1 associated with increased risk of sexually acquired HIV-1.

Authors:  Romel D Mackelprang; Michael J Bamshad; Jessica X Chong; Xuanlin Hou; Kati J Buckingham; Kathryn Shively; Guy deBruyn; Nelly R Mugo; James I Mullins; M Juliana McElrath; Jared M Baeten; Connie Celum; Mary J Emond; Jairam R Lingappa
Journal:  PLoS Pathog       Date:  2017-11-06       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.